CClinicalTrials.gg
RecruitingNCT05533749GILLUpdated Jun 14, 2024

Evaluating the Effectiveness of the GILL eHealth Intervention to Improve Physical Health and Lifestyle Behaviours in Patients With Severe Mental Illness

An interventional study of GILL eHealth in Severe Mental Disorder, Metabolic Syndrome and Lifestyle, sponsored by Amsterdam UMC, location VUmc. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-14.

Sponsored by Amsterdam UMC, location VUmc · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of this study is to evaluate the effectiveness of the nurse-led GILL (Gezondheid in Lichaam en Leefstijl) eHealth intervention in patients with serious mental illness (SMI), compared to usual care. Expected is that the GILL eHealth intervention will be more effective than usual care in improving physical health and lifestyle behaviors. To evaluate this, we will perform a cluster randomized controlled trial with an embedded process evaluation of the implementation of the GILL intervention. 258 adult patients with serious mental illness and a body mass index of 27 or higher (overweight/obesity) will be included. The GILL eHealth intervention consists of two complementary modules for (a) somatic screening and (b) lifestyle promotion, resulting in a personalized somatic treatment and lifestyle plan. Trained mental health nurses and clinical nurse specialists will implement the intervention within the multidisciplinary treatment context, and will guide and support the patients in the promotion of their somatic health, including cardiometabolic risk management. The intervention will be compared to usual care, which includes treatment according to national guidelines. The outcome measures will be metabolic syndrome severity (primary), fitness, physical activity, lifestyle behaviors, quality of life, recovery, psychosocial functioning, health related self-efficacy and health care utilization after 1 year. The process evaluation focuses on the feasibility of the eHealth intervention, its acceptability for patients and health care providers (mainly mental health nurses and clinical nurse specialists), and barriers/facilitators to implementation.

02

Conditions studied

  • Severe Mental Disorder
  • Metabolic Syndrome
  • Lifestyle
  • Somatic Screening
  • eHealth
03

In context

Metabolic Syndrome

1,964 studies on the registry are indexed under Metabolic Syndrome; 330 are open to participants now.

This study's planned enrollment of 258 is above the median of 60 across 1,460 interventional studies indexed under Metabolic Syndrome.

Browse Metabolic Syndrome studies →

Lead sponsor

Amsterdam UMC, location VUmc is the lead sponsor of 302 studies on the registry; 84 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Meet the criteria of severe mental illness
  • Aged from 18 to 65 years
  • Body mass index (BMI) ≥ 27
  • Access and ability to use internet
  • Able and willing to sign informed consent

Exclusion criteria

Exclusion Criteria:

  • Contra-indications (to be assessed by the treating physician/psychiatrist) for participation due to acute psychiatric crisis or severe somatic diseases
  • Subjects with a cognitive impairment sufficient to interfere with their ability to provide informed consent, complete study questionnaires, or participate in the intervention
  • Pregnant or breastfeeding women at the time of inclusion
  • Subject not able to communicate in the Dutch language
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
258 participants (estimated)

Study arms

  • Experimental
    GILL eHealth module

    Patients will perform the GILL eHealth. This eHealth contains two modules focusing on systematic somatic screening and lifestyle behaviors.

    Device: GILL eHealth

  • No intervention
    Care as usual

    Patients will receive usual care and have unrestricted access to mental care and treatment.

Interventions

  • DeviceGILL eHealth

    The aim of the successfully pilot-tested GILL eHealth intervention is to support mental health nurses and clinical nurse specialists in structured somatic screening and lifestyle promotion. The GILL eHealth intervention consists of two parts. Part one is OurGILL which focuses on systematic somatic screening and provides an overview of all somatic abnormalities. It promotes the prevention, early recognition and treatment of somatic problems. The second part is MyGILL. It provides the basis for drawing up a personalized lifestyle plan. The result of MyGILL is an overview of the performance of patients in different lifestyle areas. The eHealth intervention consists of an individual internet environment and is also supported by an app for mobile devices.

06

What researchers measure

Primary outcomes

  1. Metabolic Syndrome Severity Score (MSSS)

    The MSSS includes the components sex, age, ethnicity, systolic blood pressure (mmHg), waistline circumference (cm), high-density lipoprotein, triglycerides and fasting blood glucose. A lower score is considered better.

    Time frame: 12 months

Secondary outcomes

  1. Weight (kg)

    Weight is an indication for physical health.

    Time frame: 12 months

  2. Length (m)

    Length will be measured to calculate the BMI.

    Time frame: 1 measurement

  3. Body Mass Index (kg/m2)

    Body Mass Index (BMI) will be determined using the measured weight and length. A BMI between 18.5 and 25 is considered healthy.

    Time frame: 12 months

  4. Diastolic blood pressure (mmHg)

    A healthy score of the diastolic blood pressure lies between 60 and 80 mmHg.

    Time frame: 12 months

  5. Lipid profiles (mmol/l)

    LDL and total cholesterol will be determined. For the LDL a score below 3,0 mmol/l is considered good for healthy participants, participants with additional risks for cardiovascular diseases should have a score below 2.6 mmol/l, and for participants with a cardiovascular disease the score should be below 1.8 mmol/l. Overall, a lower LDL score is considered better. For the total cholesterol a score below 5.0 mmol/l is considered healthy.

    Time frame: 12 months

  6. HbA1c (mmol/l)

    HbA1c is a measurement outcome to determine blood glucose. A score below 53 is considered healthy.

    Time frame: 12 months

  7. Six-minute walk test (6MWT)

    The 6MWT is a measurement to assess physical fitness. It measures the walking distance in 6 minutes. A higher score indicates a longer distance walked and a better physical fitness.

    Time frame: 12 months

  8. International Physical Activity Questionnaire Short Form (IPAQ-SF)

    The IPAQ-SF is a 10-item self-report questionnaire where participants recall the number of days and minutes of vigorous activity, moderate activity, walking and sitting time, over the past 7 days. A higher score indicates more physical activity.

    Time frame: 12 months

  9. Numeric Rating Scale (NRS)

    The NRS will be used to determine the perceived physical health, physical activity and healthy eating of the past 4 weeks on a scale from 0-10. A higher score is considered better.

    Time frame: 12 months

  10. Short Form-12

    This is a generic, reliable and validated instrument to assess quality of life, containing 12 items derived from the Short Form 36 questionnaire. Physical and mental quality of life will be measured using the physical and mental component summary of the SF-12, respectively. A higher scores indicates a better health status.

    Time frame: 12 months

  11. Questionnaire about Processes of Recovery (QPR)

    The QPR is a self-report 15-item questionnaire with a score range of 0-60 (QPR total). Higher scores are indicative of recovery.

    Time frame: 12 months

  12. Health of the Nation Outcome Scale (HoNOS)

    The HoNOS is a clinician-rated instrument comprising twelve items on four domains (behavioral problems, organic problems, psychological symptoms, social problems), each item ranging from 0 (no problems) to 4 (severe problems). A lower score is considered better.

    Time frame: 12 months

  13. Patient Activation Measure (PAM-13)

    The questionnaire assesses the participants' self-reported knowledge, skills and confidence for health-related self-efficacy. A higher score is considered better.

    Time frame: 12 months

Other outcomes

  1. Demographics

    Age, gender, ethnicity, marital status, education level, employment status, psychiatric diagnoses, diagnosesof somatic diseases, current smoking status, number of years receiving mental care, and medication use.

    Time frame: 12 months

  2. Treatment Inventory of Costs in Patients with psychiatric disorders (TIC-P)

    The TIC-P is a validated questionnaire designed for self-report in adult patients with a mental disorder to assess their utilization of the medical health care costs. The TIC-P items that will be used include 14 structured questions on the volume of medical costs, e.g. ambulatory services, private practice, and general practitioner. A higher outcome value means more health care costs.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Parnassia Groep
    Den Haag, Zuid-Holland 2553 RJ, Netherlands
    • Berno Van Meijel, Prof. dr. · Contact
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be intellectual property of the research team, and will be available for others in case of requests after publication of the results according to privacy regulations.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05533749
Lead sponsor
Amsterdam UMC, location VUmc
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
Responsible party
Berno van Meijel (Prof. dr., Amsterdam UMC, location VUmc) — Principal investigator
First posted
Sep 9, 2022
Start date
May 30, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jun 14, 2024

Study contacts

Meike M Hoogervorst
Contact
m.m.hoogervorst@amsterdamumc.nl
+31629680823

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion